paraaminosalicylic

Paraaminosalicylic acid, often abbreviated as PAS, is a medication used primarily in the treatment of tuberculosis. It is a bacteriostatic agent, meaning it inhibits the growth of bacteria rather than killing them directly. PAS works by interfering with the synthesis of folic acid in susceptible bacteria, a process essential for their survival and reproduction.

PAS was one of the first effective anti-tuberculosis drugs to be discovered, emerging in the mid-1940s. It is typically administered orally. Due to the development of resistance and the availability of more potent and better-tolerated drugs, PAS is now usually used as part of a combination therapy regimen for multidrug-resistant tuberculosis (MDR-TB) or in cases where other first-line drugs cannot be used.

The efficacy of PAS is dependent on achieving and maintaining adequate drug concentrations in the body. Its absorption can be variable, and it is often taken with food to minimize gastrointestinal side effects. Common side effects include nausea, vomiting, diarrhea, and abdominal pain. Less frequently, it can cause hypersensitivity reactions, blood dyscrasias, and liver dysfunction. Monitoring of liver function and blood counts is often recommended during treatment.

While its role has diminished with the advent of newer drugs, paraaminosalicylic acid remains an important option in the management of challenging tuberculosis cases, particularly those involving drug-resistant strains. Its historical significance in the fight against tuberculosis is considerable.